Gliomas With 1p/19q codeletion: A.k.a. oligodendroglioma

Cancer Journal

Volumn 14, Issue 6, 2008, Pages 352-

  Cairncross, Gregory ^a,c   Jenkins, Robert ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b MAYO CLINIC   (United States)

^c FOOTHILLS HOSPITAL   (Canada)

Author keywords

1p and 19q codeletion; 1p 19q LOH; chromosome 19q; Chromosome 1p; Glioma; Oligodendroglioma; Predictive biomarker; Prognosis; t(1; 19)(q10; p10); Therapy; Treatment

Indexed keywords

LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

BIOLOGY; CANCER RADIOTHERAPY; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CONFERENCE PAPER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLIOBLASTOMA; GLIOMA; HEADACHE; HISTORY; HUMAN; MOLECULAR GENETICS; OLIGODENDROGLIOMA; PRIORITY JOURNAL; SEIZURE; SURGICAL TECHNIQUE; SURVIVAL; TUMOR GROWTH; UNCERTAINTY;

BRAIN NEOPLASMS; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DRUGS, INVESTIGATIONAL; HUMANS; OLIGODENDROGLIOMA; TRANSLOCATION, GENETIC;

EID: 58149262943     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31818d8178     Document Type: Conference Paper

References (29)

1. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;pl0) mediates the combined deletions of lp and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006;66:9852-9861.
2. Griffin CA, Burger P, Morsberger L, et al. Identification of der(1; 19)(ql0;pl0) in five oligodendrogliomas suggests mechanism of concurrent lp and 19q loss. J Neuropathol Exp Neurol. 2006;65:988-994.
3. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994;12:2013-2021.
4. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90:1473-1479.
5. Smith JS, Perry A, Borell TJ. et al. Alterations of chromosome arms lp and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 2000;18:636-645.
6. Bailey P, Bucy PC. Oligodendroglioma. J Path Bact. 1929;32:735-745.
7. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol. 2007:114: 97-109.
8. Cairncross JG, Macdonald DR. Successful chemotherapy for malignant oligodendroglioma. Ann Neurol. 1988;23:360-364.
9. van den Bent MJ, Taphoom MJB, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol. 2003;21:2525-2528.
10. Kros JM, Gorlia T, Kouwenhoven MC, Zheng P. et al. Panel review of anaplastic oligodendroglioma from European Organization for Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of lp/19q loss, and correlations with outcome. J Neuropathol Exp Neurol. 2007;66:545-551.
11. Reinfenberger J, Reinfenberger G, Liu L. et al. Molecular geneticanalysis of oligodendroglial tumors shows preferential allelic deletions on 10q and lp. Am J Pathol. 1994;145:1175-1190.
12. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24:2707-2714.
13. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organization for Research and Treatment of Cancer Phase III Trial. J Clin Oncol. 2006;24:2715-2722.
14. Engelhard HH, Stelea A, Cochran EJ. Oligodendroglioma: pathology and molecular biology. Surg Neurol. 2002:58:111-117.
15. Möllemann M, Wolter M, Feisberg J, et al. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer. 2004;113:379-385.
16. Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and response to temozolomide in glioblastoma. N Engl J Med. 2005:352: 997-1003.
17. Jaeckle KA, Ballman KV, Rao RD, et al. Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response. J Clin Oncol. 2006;24:4746-4753.
18. Stupp R, Mason W, van den Bent JM, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
19. van den Bent MJ, Chinot O, Boogerd W, et al. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol. 2003:14:599-602.
20. Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol. 2001;19:2449-2455.
21. Triebels VHJM, Taphoorn MJB, Brandes AA. et al. Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Neurology. 2004;63:904-906.
22. Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy a phase II study. Cancer. 2004;101:2079-2085.
23. Desjardins A, Quinn JA, Vredenburgh JJ. et al. Phase II study of imatinib and hydroxyurea for recurrent malignant gliomas. J Neurooncol. 2007;83:53-60.
24. Scopece L, Franceschi E, Cavallo G, et al. Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors. J Neurooncol. 2006;79:299-305.
25. Abrey LE, Childs BH, Paleologos N, et al. High-dose chemotherapy with stem cell rescue as initial therapy for oligodendroglioma: long-term follow-up. Neurooncology. 2006;8:183-188.
26. Baumann N, Pham-Dinh D. Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev. 2001 ;81:871-926.
27. Ng H-K, Ko HC, Tse CC. Immunohistochemical and ultrastructural studies of oligodendroglioma reveal neuronal differentiation, Int J Surg Path. 1994;2:47-56.
28. Ducray F, Idbaih A, de Reyniès A, et al. Anaplastic oligodendrogliomas with lpl9q codeletion have a proneural gene expression profile. Mol Cancer. 2008 7:41.
29. Rodriguez ḞJ, Mota RA, Scheithauer BW, et al. Interphase cytogenetics for lpl9q and t(1;19)(q10;p10) may distinguish prognostically relevant subgroups in extraventricular neurocytoma. Brain Pathol. 2008 Aug 15 [Epub ahead of print].